Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 446

3.

Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.

Yuen GJ, Lou Y, Thompson NF, Otto VR, Allsup TL, Mahony WB, Hutman HW.

J Clin Pharmacol. 2001 Mar;41(3):277-88.

PMID:
11269568
4.

Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.

Kumar PN, Sweet DE, McDowell JA, Symonds W, Lou Y, Hetherington S, LaFon S.

Antimicrob Agents Chemother. 1999 Mar;43(3):603-8.

5.

A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.

Sáez-Llorens X, Nelson RP Jr, Emmanuel P, Wiznia A, Mitchell C, Church JA, Sleasman J, Van Dyke R, Richardson CG, Cutrell A, Spreen W, Hetherington S.

Pediatrics. 2001 Jan;107(1):E4.

PMID:
11134468
6.
7.

Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.

Vourvahis M, Davis J, Langdon G, Layton G, Fang J, Choo HW, Hansson AG, Tawadrous M.

Antivir Ther. 2013;18(6):745-54. doi: 10.3851/IMP2566. Epub 2013 Apr 4.

PMID:
23558061
8.

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.

Staszewski S, Katlama C, Harrer T, Massip P, Yeni P, Cutrell A, Tortell SM, Harrigan RP, Steel H, Lanier RE, Pearce G.

AIDS. 1998 Nov 12;12(16):F197-202.

PMID:
9833847
9.

Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.

Hughes W, McDowell JA, Shenep J, Flynn P, Kline MW, Yogev R, Symonds W, Lou Y, Hetherington S.

Antimicrob Agents Chemother. 1999 Mar;43(3):609-15.

10.

Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.

Markowitz M, Hill-Zabala C, Lang J, DeJesus E, Liao Q, Lanier ER, Davis EA, Shaefer M; ESS40013 Study Team.

J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):257-64.

PMID:
15980684
12.

Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects.

Huang F, Allen L, Huang DB, Moy F, Vinisko R, Nguyen T, Rowland L, MacGregor TR, Castles MA, Robinson P.

J Clin Pharm Ther. 2012 Feb;37(1):81-8. doi: 10.1111/j.1365-2710.2010.01235.x. Epub 2010 Dec 5.

PMID:
21128991
13.

Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients.

Cato A 3rd, Qian J, Hsu A, Levy B, Leonard J, Granneman R.

Antimicrob Agents Chemother. 1998 Jul;42(7):1788-93.

15.

Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.

Saag MS, Sonnerborg A, Torres RA, Lancaster D, Gazzard BG, Schooley RT, Romero C, Kelleher D, Spreen W, LaFon S.

AIDS. 1998 Nov 12;12(16):F203-9.

PMID:
9833848
16.

An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.

Foudraine NA, de Jong JJ, Jan Weverling G, van Benthem BH, Maas J, Keet IP, Jurriaans S, Roos MT, Vandermeulen K, de Wolf F, Lange JM.

AIDS. 1998 Aug 20;12(12):1513-9.

PMID:
9727573
17.

A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team.

Kline MW, Blanchard S, Fletcher CV, Shenep JL, McKinney RE Jr, Brundage RC, Culnane M, Van Dyke RB, Dankner WM, Kovacs A, McDowell JA, Hetherington S.

Pediatrics. 1999 Apr;103(4):e47.

PMID:
10103339
18.

A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.

Haubrich R, Thompson M, Schooley R, Lang W, Stein A, Sereni D, van der Ende ME, Antunes F, Richman D, Pagano G, Kahl L, Fetter A, Brown DJ, Clumeck N.

AIDS. 1999 Dec 3;13(17):2411-20.

PMID:
10597783
19.

Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption.

Moore KH, Shaw S, Laurent AL, Lloyd P, Duncan B, Morris DM, O'Mara MJ, Pakes GE.

J Clin Pharmacol. 1999 Jun;39(6):593-605.

PMID:
10354963
20.

Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food.

Chittick GE, Gillotin C, McDowell JA, Lou Y, Edwards KD, Prince WT, Stein DS.

Pharmacotherapy. 1999 Aug;19(8):932-42.

PMID:
10453964

Supplemental Content

Support Center